Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients
Open Access
- 26 May 2009
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 32 (8), 1479-1484
- https://doi.org/10.2337/dc09-0545
Abstract
OBJECTIVE To evaluate the efficacy and safety of actovegin in patients with diabetic polyneuropathy. RESEARCH DESIGN AND METHODS In this multicenter, randomized, double-blind trial, 567 patients with type 2 diabetes received 20 intravenous infusions of actovegin (2,000 mg/day) (n = 281) or placebo (n = 286) once daily followed by three tablets of actovegin (1,800 mg/day) or placebo three times daily for 140 days. Total symptom score (TSS) of the lower limbs and vibration perception threshold (VPT) were used as coprimary outcome measures, computed as the area under the curve (AUC) from repeated scores and divided by duration of exposure. Secondary end points included individual TSS symptoms, neuropathy impairment score of the lower limbs (NIS-LL), and quality of life (short form [SF]-36). RESULTS TSS was significantly improved during actovegin treatment compared with placebo, as assessed by AUC (−0.56 points [95% CI −0.85 to −0.27]; P = 0.0003), and from baseline to 160 days (−0.86 points [−1.22 to −0.50]; P < 0.0001). VPT (five sites per foot) decreased by 3% (95% CI 0–6; P = 0.084) with actovegin than placebo, as assessed by AUC, and by 5% (1–9; P = 0.017) after 160 days. NIS-LL sensory function, as assessed by AUC, was significantly improved with actovegin versus placebo (−0.25 [95% CI −0.46 to −0.04]; P = 0.021), as was the SF-36 mental health domain. There were no differences in the incidence of adverse events between the groups. CONCLUSIONS Sequential intravenous and oral actovegin treatment over 160 days improved neuropathic symptoms, VPT, sensory function, and quality of life in type 2 diabetic patients with symptomatic polyneuropathy.Keywords
This publication has 22 references indexed in Scilit:
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2009
- Placebo response in neuropathic pain trials ☆Pain, 2008
- Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and MacroangiopathyDiabetes Care, 2008
- Pharmacologic management of neuropathic pain: Evidence-based recommendationsPain, 2007
- Aldose reductase inhibitors for the treatment of diabetic polyneuropathyEmergencias, 2007
- The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 DiabetesDiabetes Care, 2006
- Confirmed Clinical Efficacy of Actovegin®in Elderly Patients with Organic Brain SyndromePharmacopsychiatry, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient GroupsMedical Care, 1994
- Nature of enhanced mitochondrial oxidative metabolism by a calf blood extractJournal of Cellular Physiology, 1991
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988